Larvol Delta - Attovia-Therapeutics-Announces-First-Participant-Dosed-in-FirstinHuman-Phase-1-Study-of-ATTO1310-its-Novel-Halflife-Extended-AntiIL31-ATTOBODY-for-the-Treatment-of-Chronic-Pruritus

ATTO-1310 - Attovia Therap

https://www.globenewswire.com/news-release/2025/01/23/3014175/0/en/Attovia-Therapeutics-Announces-First-Participant-Dosed-in-First-in-Human-Phase-1-Study-of-ATTO-1310-its-Novel-Half-life-Extended-Anti-IL-31-ATTOBODY-for-the-Treatment-of-Chronic-Pr.html

Jan 23, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next